IQVIA Logo

Insight

Early Unwanted Immunogenicity Risk Assessment of Biotherapeutics

Home / Insights / Early Unwanted Immunogenicity Risk Assessment of Biotherapeutics

The immunogenicity team presented a poster at Antibody Engineering and Therapeutics Europe in June 2024. This poster—Early Unwanted Immunogenicity Risk Assessment of Biotherapeutics—discusses our approach to minimizing immunogenicity risks.

 

Complete the form to view/download this poster.